© 2026 CellCarta - All rights reserved.
Download the Case Study
What If Your Biomarker Assay Could Be Trial-Ready Months Sooner?
Case Study: From RUO to Trial-Ready in Six Months
Don’t let assay development delay your clinical trial
When a global biopharmaceutical company needed to replace an obsolete qPCR-based patient-selection assay for a Phase 3 cancer trial, speed was essential, but speed alone was not sufficient.
CellCarta and Pillar Biosciences responded with an integrated development model that ran assay design, clinical validation, regulatory documentation, and laboratory implementation as parallel workstreams rather than sequential ones.
The result: a validated, trial-ready FGFR NGS patient-selection assay delivered in less than six months! Cutting the standard 10–12 month process nearly in half and keeping the sponsor's first-patient enrollment timeline on track.
Advancing Oncology Biomarker Strategies During ASCO 2026
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. Our broad suite of genomics services can support your clinical trial, whether you require digital PCR, quantitative PCR, next-generation sequencing, or spatial analysis.
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. Our broad suite of genomics services can support your clinical trial, whether you require digital PCR, quantitative PCR, next-generation sequencing, or spatial analysis.
